In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma

Lisocabtagene maraleucel (liso‐cel) is an autologous, CD19‐directed, chimeric antigen receptor T‐cell product for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma (LBCL) after 2 or more lines of systemic therapy. In vivo cellular expansion after single‐dose administr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogasawara, Ken, Lymp, James, Mack, Timothy, Dell’Aringa, Justine, Huang, Chang‐pin, Smith, Jeff, Peiser, Leanne, Kostic, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311712/
https://www.ncbi.nlm.nih.gov/pubmed/35156195
http://dx.doi.org/10.1002/cpt.2561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311712/
https://www.ncbi.nlm.nih.gov/pubmed/35156195
http://dx.doi.org/10.1002/cpt.2561

Ejemplares similares